# BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Announces $20 Million Preferred Stock and Warrant Offering

Oragenics (NYSE American: OGEN) a developer of intranasal pharmaceuticals for neurological disorders, has entered into a placement agency agreement for the sale of up to 800,000 shares of Series H Convertible Preferred Stock and accompanying Warrants, priced at $25.00 per unit. Each Warrant allows purchase of an additional Preferred share at $25.00, with Preferred shares convertible into common stock at $2.50. Gross proceeds could total $20 million, which will support ONP-2 concussion trials, R&D, repayment of a $3 million bridge note, and general corporate needs. Dawson James Securities, Inc. is acting as sole placement agent, with closing expected on or about July 2, 2025.

 To view the full press release, visit https://ibn.fm/QZpH0

 About Oragenics

 Oragenics is a development-stage biotechnology company focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (“mTBI”), also known as concussion, and for treating Niemann Pick Disease Type C (“NPC”), as well as proprietary powder formulation and an intranasal delivery device. For more information, visit the company’s website at www.Oragenics.com

 NOTE TO INVESTORS: The latest news and updates relating to OGEN are available in the company’s newsroom at https://ibn.fm/OGEN

 About BioMedWire

 BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

 BMW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.BioMedWire.com

 Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

 BioMedWireAustin, Texaswww.BioMedWire.com512.354.7000 OfficeEditor@BioMedWire.com

 BioMedWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/bmw/biomednewsbreaks-oragenics-inc-nyse-american-ogen-announces-20-million-preferred-stock-and-warrant-offering/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/oragenics-secures-20m-funding-for-neurological-disorder-treatments/8952bca6dcad77026f920aff0d88a890) 

 



[Reddit Post](https://www.reddit.com/r/Business_NewsRamp/comments/1lp4l8n/oragenics_secures_20m_funding_for_neurological/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/257/1/rushqH7f.webp)